Use systemic immunosupression with great caution experts advise

Article

Systemic immunosuppression following corneal transplantation should be administered only under strict medical surveillance.

Systemic immunosuppression following corneal transplantation should be administered only under strict medical surveillance, according to specialists speaking at the ESCRS Winter Refractive Surgery Meeting's Cornea Day in Athens, Greece.

Jorge L. Alio, MD commented that patients should be made aware that lifelong immunosuppression is unavoidable in some cases. He emphasized that it is especially important to understand that the elderly are more at risk of severe complications and that it may induce fertility problems in women.

However, according to Nikolaos Papadopoulos, MD, the main danger comes in the form lung aspergillosis, a potentially fatal condition. He cited one case where a 65-year old woman, treated with oral cyclosporine, was found to have the condition after a second graft was rejected. Fortunately, in this case they were able to treat the disease and a third graft was successful.

As an alternative, Dr Papadopoulos suggests that topical immunosupression is a viable alternative to systemic treatment. However Dr Alio disagreed, saying that it is simply not as effective over the long-term and is not able to reach the anterior chamber, adding that he personally prefers to use tacrolimus in a 1% concentration.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.